Ahmed M. Bayoumi

MD, MSc

Scientist

Biography

Dr. Ahmed Bayoumi is a Scientist at MAP Centre for Urban Health Solutions at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, where he is also a general internist and Human Immunodeficiency Virus (HIV) physician. He holds the Fondation Baxter and Alma Ricard Chair in Inner City Health at St. Michael’s Hospital and the University of Toronto and is a Professor in the Department of Medicine and in the Institute of Health Policy, Management and Evaluation at the University of Toronto. He is a Senior Adjunct Scientist at ICES. He has extensive experience in translating research to policy (member of the Canadian Drug Expert Committee, past Scientific Director of Converge3, past president of the international Society for Medical Decision Making, and past Director of Clinical Epidemiology and Health Care Research at the University of Toronto). He has co-led large multi-method studies, including the highly impactful Toronto and Ottawa Supervised Consumption Assessment (TOSCA) and the Marginalization and COVID-19 (MARCO) studies. His research interests include the delivery of health services, particularly to people who use drugs, people living with HIV, and other marginalized populations. He is a member of HMRAC (the Homelessness, Mortality, Research and Advocacy Coalition), an academic – community collaboration that meets regularly to discuss how research can address issues related to homelessness.

Recent Publications

  1. Mighton, C, Clausen, M, Sebastian, A, Muir, SM, Shickh, S, Baxter, NN et al.. Patient and public preferences for being recontacted with updated genomic results: a mixed methods study. Hum Genet. 2021; :. doi: 10.1007/s00439-021-02366-0. PubMed PMID:34537903 .
  2. Refaie, MMM, Shehata, S, Ibrahim, RA, Bayoumi, AMA, Abdel-Gaber, SA. Dose-Dependent Cardioprotective Effect of Hemin in Doxorubicin-Induced Cardiotoxicity Via Nrf-2/HO-1 and TLR-5/NF-κB/TNF-α Signaling Pathways. Cardiovasc Toxicol. 2021; :. doi: 10.1007/s12012-021-09694-7. PubMed PMID:34510376 .
  3. Perri, M, Kaminski, N, Bonn, M, Kolla, G, Guta, A, Bayoumi, AM et al.. A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. Harm Reduct J. 2021;18 (1):85. doi: 10.1186/s12954-021-00530-3. PubMed PMID:34353323 PubMed Central PMC8339679.
  4. Morsy, MA, Khalaf, HM, Rifaai, RA, Bayoumi, AMA, Khalifa, EMMA, Ibrahim, YF et al.. Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2. Biomed Pharmacother. 2021;141 :111902. doi: 10.1016/j.biopha.2021.111902. PubMed PMID:34328119 .
  5. Harris, MTH, Young, S, Barocas, J, Bayoumi, AM, Caudarella, A, Laurence, G et al.. A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto. Public Health Rep. ;136 (5):532-537. doi: 10.1177/00333549211032974. PubMed PMID:34269625 .
  6. Perri, M, Guta, A, Gagnon, M, Bonn, M, Leece, P, Bayoumi, AM et al.. Developing a digital health strategy for people who use drugs: Lessons from COVID-19. Digit Health. ;7 :20552076211028404. doi: 10.1177/20552076211028404. PubMed PMID:34262782 PubMed Central PMC8243112.
  7. Rowlands Snyder, EC, Boucher, LM, Bayoumi, AM, Martin, A, Marshall, Z, Boyd, R et al.. A cross-sectional study of factors associated with unstable housing among marginalized people who use drugs in Ottawa, Canada. PLoS One. 2021;16 (7):e0253923. doi: 10.1371/journal.pone.0253923. PubMed PMID:34197552 PubMed Central PMC8248707.
  8. Ewees, MGE, Abdel-Bakky, MS, Bayoumi, AMA, Abo-Saif, AA, Altowayan, WM, Alharbi, KS et al.. Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway. J Adv Res. 2021;31 :127-136. doi: 10.1016/j.jare.2020.12.014. PubMed PMID:34194837 PubMed Central PMC8240102.
  9. Refaie, MMM, Shehata, S, Bayoumi, AMA, El-Tahawy, NFG, Abdelzaher, WY. The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity. Cardiovasc Drugs Ther. 2021; :. doi: 10.1007/s10557-021-07214-x. PubMed PMID:34185243 .
  10. Tan, DHS, Tavangar, F, Fusca, L, Ross, P, Hull, MW, Grennan, T et al.. Interest in Hypothetical Preexposure Prophylaxis Against Herpes Simplex Virus: A Cross-Sectional Survey. Sex Transm Dis. 2021;48 (8):e105-e108. doi: 10.1097/OLQ.0000000000001342. PubMed PMID:34110756 PubMed Central PMC8284350.
Search PubMed

Affiliations & Other Activities

  • Scientist, MAP Centre for Urban Health Solutions, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Professor, Institute of Health Policy, Management and Evaluation, University of Toronto
X